PHA-848125 NEW

$2.00 25KG

$4.00 5KG

$6.00 1KG

Min. Order1KG
Purity99%
Cas No802539-81-7
Supply Abilityg-kg-ton
Update time2025-10-13

ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD

VIP1Y

China

Chemical Properties

Product Name	PHA-848125
CAS No	802539-81-7
EC-No
Min. Order	1KG
Purity	99%
Supply Ability	g-kg-ton
Release date	2025/10/13

PHA-848125

Modify Date: 2024-01-11 15:40:00

PHA-848125 structure	Common Name	PHA-848125
	CAS Number	802539-81-7	Molecular Weight	460.575
	Density	1.3±0.1 g/cm3	Boiling Point	N/A
	Molecular Formula	C25H32N8O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Purity		Quantity		Budget		Inquiry

Use of PHA-848125

Milciclib (PHA-848125) is a potent, dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

Properties
Spectrum

Name	N,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Synonym	More Synonyms

Description	Milciclib (PHA-848125) is a potent, dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
Related Catalog	Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Cancer
Target	cyclin A/CDK2:45 nM (IC50) cyclin E/CDK2:363 nM (IC50) cyclin H/CDK7:150 nM (IC50) cyclin D1/CDK4:160 nM (IC50) cyclin B/CDK1:398 nM (IC50) TRKA:53 nM (IC50)
In Vitro	Milciclib (PHA-848125; 0.156 or 0.625 μM) up-regulates the expression of PDCD4, DDIT4, SESN2/sestrin 2 and DEPDC6/DEPTOR in GL-Mel cells[1]. Milciclib (PHA-848125) potently inhibits the kinase activity of CDK2/cyclin A complex and of TRKA in a biochemical assay, with IC50s of 45 and 53 nM, respectively. Milciclib induces a clear accumulation of cells in G1 phase. Milciclib strongly inhibits NGF-induced phosphorylation of TRKA in a dose-dependent manner[2].
In Vivo	Milciclib (PHA-848125; 5, 10, and 15 mg/kg, p.o.) inhibits the growth of tumor in 7,12-dimethylbenz(a) anthracene (DMBA)-induced rat mammary carcinoma model. Milciclib has significant antitumor activity in various human xenografts and carcinogen-induced tumors as well as in disseminated primary leukemia models, with plasma concentrations in rodents in the same range as those found active in inhibiting cancer cell proliferation[2]. Milciclib (PHA-848125; 40 mg/kg) induces a significant tumor growth inhibition in K-RasG12DLA2 mice, and this is accompanied by a reduction in the cell membrane turnover[3].
Cell Assay	Cells are seeded into 96- or 384-well plates at densities ranging from 10,000 to 30,000/cm2 in appropriate medium plus 10% FCS. After 24 hours, cells are treated in duplicate with serial dilutions of Milciclib, and 72 hours later, viable cell number is assessed using the CellTiter-Glo Assay. IC50s are calculated using a Sigmoidal fitting algorithm. Experiments are done independently at least twice.
Animal Admin	Rats are randomized and introduced into the study when at least one mammary tumor attained a diameter of 0.5 cm. Groups of 10 animals are treated orally twice a day continuously for 10 days with vehicle (glucosate) or with 5, 10, and 15 mg/kg of Milciclib, whereas a further group receives two cycles of Milciclib at 20 mg/kg orally twice a day for 5 days with an intervening rest period of 1 week. Tumor volume is measured regularly by caliper for the duration of the experiment.
References	[1]. Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, Del Bufalo D, Desideri M, Bonmassar E, Pfeffer U, D'Atri S.Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.Biochem Pharmacol. 2012 Sep 1;84(5):598-611. [2]. Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG, Festuccia C, Fiorentini F, Locatelli G, Pastori W, Patton V, Roletto F, Colotta F, Galvani A, Isacchi A, Moll J, Pesenti E, Mercurio C, Ciomei M.Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy.Mol Cancer Ther. 2010 Aug;9(8):2243-54. [3]. Degrassi A, et al. Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.Mol Cancer Ther. 2010 Mar;9(3):673-81.

Density	1.3±0.1 g/cm3
Molecular Formula	C25H32N8O
Molecular Weight	460.575
Exact Mass	460.269897
PSA	94.70000
LogP	1.75
Index of Refraction	1.692
Storage condition	-20℃

Company Profile

Our company is a high-tech enterprise specializing in chemical raw materials such as electronic materials, optoelectronic materials, semiconductor materials, UV monomers, silane catalysts, cosmetic raw materials, etc. The company integrates research and development, production, customized synthesis, and sales, and is committed to providing customers with high-quality chemical product solutions.

Our Company

Our Advantage

Rich experience

Our products have been exported to many countries, including Germany, Spain, the United Kingdom, the United States, Australia, the Middle East, Asia, and more. We have received highly positive feedback from our clients and have established long-term friendly cooperative relationships with them.

Excellent quality, purity, and competitive price

Excellent quality is one of the cornerstones of our success. We welcome ordering samples for quality testing.